Pancreatic cancer drug shrank tumors for 1 in 3 lung cancer patients: Early trial
An oral targeted therapy approved for pancreatic cancer showed antitumor activity in previously treated lung cancer, according to early-phase data published Sept. 2 in The New England Journal of Medicine. The drug, Rasonque (daraxonrasib), is an oral RAS inhibitor from Redwood City, Calif.-based Revolution Medicines. The FDA approved it Aug. 26 for metastatic pancreatic cancer, […] The post Pancreatic cancer drug shrank tumors for 1 in 3 lung cancer patients: Early trial appeared first on...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.